Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines
Research output: Contribution to journal › Letter › Research
Standard
Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines. / Moghimi, Seyed Moien; Andersen, T. L.
In: Molecular Immunology, Vol. 46, 2009, p. 1571.Research output: Contribution to journal › Letter › Research
Harvard
Moghimi, SM & Andersen, TL 2009, 'Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines', Molecular Immunology, vol. 46, pp. 1571. https://doi.org/10.1016/j.molimm.2009.02.014
APA
Moghimi, S. M., & Andersen, T. L. (2009). Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines. Molecular Immunology, 46, 1571. https://doi.org/10.1016/j.molimm.2009.02.014
Vancouver
Moghimi SM, Andersen TL. Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines. Molecular Immunology. 2009;46:1571. https://doi.org/10.1016/j.molimm.2009.02.014
Author
Bibtex
@article{d3f2d380753011de8bc9000ea68e967b,
title = "Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines",
abstract = "Udgivelsesdato: 2009",
keywords = "Former Faculty of Pharmaceutical Sciences",
author = "Moghimi, {Seyed Moien} and Andersen, {T. L.}",
year = "2009",
doi = "10.1016/j.molimm.2009.02.014",
language = "English",
volume = "46",
pages = "1571",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Pergamon Press",
}
RIS
TY - JOUR
T1 - Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines
AU - Moghimi, Seyed Moien
AU - Andersen, T. L.
PY - 2009
Y1 - 2009
N2 - Udgivelsesdato: 2009
AB - Udgivelsesdato: 2009
KW - Former Faculty of Pharmaceutical Sciences
U2 - 10.1016/j.molimm.2009.02.014
DO - 10.1016/j.molimm.2009.02.014
M3 - Letter
C2 - 19286261
VL - 46
SP - 1571
JO - Molecular Immunology
JF - Molecular Immunology
SN - 0161-5890
ER -
ID: 13253531